WO2000055629A3 - Methods of diagnosing and treating breast cancer - Google Patents

Methods of diagnosing and treating breast cancer Download PDF

Info

Publication number
WO2000055629A3
WO2000055629A3 PCT/US2000/006952 US0006952W WO0055629A3 WO 2000055629 A3 WO2000055629 A3 WO 2000055629A3 US 0006952 W US0006952 W US 0006952W WO 0055629 A3 WO0055629 A3 WO 0055629A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
breast cancer
diagnosing
treating breast
breast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/006952
Other languages
French (fr)
Other versions
WO2000055629A2 (en
Inventor
David Mack
Kurt C Gish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EOS Biotechnology Inc
Original Assignee
EOS Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EOS Biotechnology Inc filed Critical EOS Biotechnology Inc
Priority to MXPA01009367A priority Critical patent/MXPA01009367A/en
Priority to AU37527/00A priority patent/AU3752700A/en
Priority to CA002368152A priority patent/CA2368152A1/en
Priority to EP00916419A priority patent/EP1159619A2/en
Priority to JP2000605210A priority patent/JP2004537710A/en
Priority to US09/642,034 priority patent/US6762020B1/en
Publication of WO2000055629A2 publication Critical patent/WO2000055629A2/en
Priority to US09/747,371 priority patent/US6750013B2/en
Publication of WO2000055629A3 publication Critical patent/WO2000055629A3/en
Anticipated expiration legal-status Critical
Priority to US10/769,612 priority patent/US20040141983A1/en
Priority to US12/796,244 priority patent/US8313745B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Described herein are methods that can be used for diagnosis and prognosis of breast cancer. Also described herein are methods that can be used to screen candidate bioactive agents for the ability to modulate breast cancer. Additionally, methods and molecular targets (genes and their products) for therapeutic intervention in breast and other cancers are described. The methods involve the use of proteins like BCH1.
PCT/US2000/006952 1999-03-15 2000-03-15 Methods of diagnosing and treating breast cancer Ceased WO2000055629A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MXPA01009367A MXPA01009367A (en) 1999-03-15 2000-03-15 Novel methods of diagnosing and treating breast cancer, compositions, and methods of screening for breast cancer modulators.
AU37527/00A AU3752700A (en) 1999-03-15 2000-03-15 Novel methods of diagnosing and treating breast cancer, compositions, and methods of screening for breast cancer modulators
CA002368152A CA2368152A1 (en) 1999-03-15 2000-03-15 Novel methods of diagnosing and treating breast cancer, compositions, and methods of screening for breast cancer modulators
EP00916419A EP1159619A2 (en) 1999-03-15 2000-03-15 Methods of diagnosing and treating breast cancer
JP2000605210A JP2004537710A (en) 1999-03-15 2000-03-15 Novel methods and compositions for diagnosing and treating breast cancer and methods for selecting for breast cancer modulators
US09/642,034 US6762020B1 (en) 1999-03-15 2000-08-18 Methods of diagnosing breast cancer
US09/747,371 US6750013B2 (en) 1999-12-02 2000-12-21 Methods for detection and diagnosing of breast cancer
US10/769,612 US20040141983A1 (en) 1999-03-15 2004-01-29 Compositions against cancer antigen LIV-1 and uses thereof
US12/796,244 US8313745B2 (en) 1999-03-15 2010-06-08 Compositions against cancer antigen LIV-1 and uses thereof

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US26886599A 1999-03-15 1999-03-15
US09/268,865 1999-03-15
US43987899A 1999-11-12 1999-11-12
US44037099A 1999-11-12 1999-11-12
US09/440,370 1999-11-12
US09/439,878 1999-11-12
US44049399A 1999-11-15 1999-11-15
US09/440,493 1999-11-15
US44067699A 1999-11-16 1999-11-16
US44067799A 1999-11-16 1999-11-16
US09/440,677 1999-11-16
US09/440,676 1999-11-16
US45081099A 1999-11-29 1999-11-29
US09/450,810 1999-11-29
US45313799A 1999-12-02 1999-12-02
US09/453,137 1999-12-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US52536100A Continuation-In-Part 1999-03-15 2000-03-15

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US45313799A Continuation-In-Part 1999-03-15 1999-12-02
US09/642,034 Continuation-In-Part US6762020B1 (en) 1999-03-15 2000-08-18 Methods of diagnosing breast cancer

Publications (2)

Publication Number Publication Date
WO2000055629A2 WO2000055629A2 (en) 2000-09-21
WO2000055629A3 true WO2000055629A3 (en) 2001-03-22

Family

ID=27575318

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/006952 Ceased WO2000055629A2 (en) 1999-03-15 2000-03-15 Methods of diagnosing and treating breast cancer

Country Status (4)

Country Link
EP (1) EP1159619A2 (en)
AU (1) AU3752700A (en)
CA (1) CA2368152A1 (en)
WO (1) WO2000055629A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE413466T1 (en) 1998-09-02 2008-11-15 Diadexus Inc METHOD FOR THE DIAGNOSIS, ASSESSMENT AND IMAGING OF VARIOUS CANCER DISEASES
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US7888477B2 (en) 1998-12-17 2011-02-15 Corixa Corporation Ovarian cancer-associated antibodies and kits
US6962980B2 (en) 1999-09-24 2005-11-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6468546B1 (en) 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
WO2001035811A2 (en) * 1999-11-16 2001-05-25 Eos Biotechnology, Inc. Methods of diagnosing and determining prognosis of breast cancer
US7238471B1 (en) 1999-11-23 2007-07-03 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating breast cancer
CA2390802A1 (en) * 1999-11-23 2001-05-31 Diadexus, Inc. A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer
IL150592A0 (en) 2000-01-25 2003-02-12 Genentech Inc Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
US7534417B2 (en) 2000-02-24 2009-05-19 Agensys, Inc. 103P2D6: tissue specific protein highly expressed in various cancers
GB0004576D0 (en) * 2000-02-25 2000-04-19 Oxford Glycosciences Uk Ltd Proteins
US20020102641A1 (en) * 2000-03-24 2002-08-01 Susan Schia Vi Oncogenic osteomalacia-related gene 1
EP1287129A1 (en) * 2000-05-19 2003-03-05 F.Hoffmann-La Roche Ag A process for determing the tumoricidal potential of a sample by the use of a nucleic acid which is downregulated in human tumor cells
US20060063230A1 (en) 2000-12-27 2006-03-23 Roman Naworth Sulfatases and methods of use thereof
US20030148920A1 (en) * 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
EP1434783A4 (en) * 2001-03-16 2006-06-07 Lilly Co Eli Lp mammalian proteins; related reagents
US6461847B1 (en) * 2001-03-19 2002-10-08 Applera Corporation Polynucleotides encoding human estrone sulfatases
JP2005526233A (en) 2001-12-31 2005-09-02 ダナ−ファーバー　キャンサー　インスティテュート，インコーポレイテッド Methods using soriacin expression by breast epithelial cells
CA2992643C (en) 2002-03-13 2019-06-18 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
WO2004106495A2 (en) * 2003-05-29 2004-12-09 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US7666583B2 (en) 2004-02-19 2010-02-23 Yale University Identification of cancer protein biomarkers using proteomic techniques
EP1805676A1 (en) * 2004-09-22 2007-07-11 Tripath Imaging, Inc. Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis
CA2632419A1 (en) 2005-12-06 2007-06-14 Kyowa Hakko Kogyo Co., Ltd. Genetically recombinant anti-perp antibody

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514554A (en) * 1991-08-22 1996-05-07 Becton Dickinson And Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
WO1998018945A1 (en) * 1996-10-31 1998-05-07 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
WO1998034118A1 (en) * 1997-01-30 1998-08-06 Yale University Diagnostic methods and compositions based on the distribution of rad51
WO1999023230A1 (en) * 1997-10-31 1999-05-14 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
WO1999025877A1 (en) * 1997-11-18 1999-05-27 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
WO1999033869A2 (en) * 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO2000008210A1 (en) * 1998-08-04 2000-02-17 Diadexus Llc A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514554A (en) * 1991-08-22 1996-05-07 Becton Dickinson And Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
WO1998018945A1 (en) * 1996-10-31 1998-05-07 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
WO1998034118A1 (en) * 1997-01-30 1998-08-06 Yale University Diagnostic methods and compositions based on the distribution of rad51
WO1999023230A1 (en) * 1997-10-31 1999-05-14 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
WO1999025877A1 (en) * 1997-11-18 1999-05-27 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
WO1999033869A2 (en) * 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO2000008210A1 (en) * 1998-08-04 2000-02-17 Diadexus Llc A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer

Also Published As

Publication number Publication date
CA2368152A1 (en) 2000-09-21
WO2000055629A2 (en) 2000-09-21
EP1159619A2 (en) 2001-12-05
AU3752700A (en) 2000-10-04

Similar Documents

Publication Publication Date Title
WO2000055629A3 (en) Methods of diagnosing and treating breast cancer
WO2001031335A3 (en) Cell proliferation diagnosis and screening for modulators
WO2000055633A3 (en) Methods of screening for colorectal cancer modulators
WO2002021996A3 (en) Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
EP2022800A3 (en) Compositions for the therapy and diagnosis of ovarian cancer
WO2003042661A8 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
IL127558A0 (en) Hepatocyte growth factor receptor agonists and uses thereof
WO2002016413A8 (en) Cripto tumour polypeptide
WO2000036107A3 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
WO2001011086A3 (en) Methods of screening for angiogenesis modulators
WO2002055988A3 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
SG144712A1 (en) Nordihydroguaiartic derivaties for use in treatment of tumors
BR9808509A (en) Compositions and methods for the treatment and diagnosis of breast cancer
EP1570081A4 (en) Amplified genes involved in cancer
AU2002338852A1 (en) Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
PL341151A1 (en) Substituted products of condensation of n-benzyl-3-indenylacetamides with heterocyclic aldehydes for use in treating neoplastic diseases
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
WO2002064839A3 (en) Methods for the diagnosis and treatment of tumors employing the hepsin gene
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2003026494A3 (en) Galectins-1-and-4 in tumor development
EP1696028A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2002016939A3 (en) Methods of diagnosis of cancer and screening for cancer modulators

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09747371

Country of ref document: US

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 605210

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/009367

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000916419

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2368152

Country of ref document: CA

Ref country code: CA

Ref document number: 2368152

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000916419

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000916419

Country of ref document: EP